

<b>Name</b>	Sang-Won Um	
<b>Country</b>	Republic of Korea	
<b>Organization</b>	Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine	
<b>Current Position</b>	Professor	

### **Educational Background**

2008-2009: Clinical Assistant Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Seoul, Korea

2009-2013: Assistant Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center  
Sungkyunkwan University School of Medicine, Seoul, Korea

2012-2013: Visiting Scholar

University of North Carolina at Chapel Hill, Chapel Hill, NC, 27516, USA

2013-2019: Associate Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center  
Sungkyunkwan University School of Medicine, Seoul, Korea

2019-current: Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center  
Sungkyunkwan University School of Medicine, Seoul, Korea

### **Professional Experiences**

2008-2009: Clinical Assistant Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Seoul, Korea

2009-2013: Assistant Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center  
Sungkyunkwan University School of Medicine, Seoul, Korea

2012-2013: Visiting Scholar

University of North Carolina at Chapel Hill, Chapel Hill, NC, 27516, USA

2013-2019: Associate Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center  
Sungkyunkwan University School of Medicine, Seoul, Korea

2019-current: Professor

Division of Pulmonary and Critical Care Medicine, Samsung Medical Center  
Sungkyunkwan University School of Medicine, Seoul, Korea

### **Professional Organizations**

1998-: Korean Medical Association

2003-: Korean Society of Internal Medicine

2006-: Korean Academy of Tuberculosis and Respiratory Diseases

2009-: Asian Pacific Society of Respiratory (APSR)

2009-: International Association for the Study of Lung Cancer (IASLC)

2010-: Korean Association for Lung Cancer (KALC)

2013-: American Association for Cancer Research (AACR)

---

2014-: Korean Cancer Association (KCA)

2023-: European Society of Medical Oncology (ESMO)

---

### Main Scientific Publications

---

#### SCI(E): first or corresponding author only

1. Um SW, Choi CM, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG. Prospective analysis of clinical characteristics and risk factors of postbronchoscopy fever. *Chest* 2004; 125: 945-52.
  2. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee CT, Lee JH. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. *Int J Tuberc Lung Dis* 2007 Sep; 11(9): 972-978.
  3. Um SW, Yoon YS, Lee SM, Yim JJ, Yoo CG, Chung HS, Kim YW, Han SK, Shim YS, Kim DK. Predictors of persistent airway stenosis in patients with endobronchial tuberculosis. *Int J Tuberc Lung Dis* 2008 Jan;12(1):57-62.
  4. Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, Choi JY, Han J, Lee KS, Kim J. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. *J Thorac Oncol* 2009 Nov;4(11):1331-6.
  5. Park HK, Jeon K, Koh WJ, Suh GY, Kim H, Kwon OJ, Chung MP, Lee KS, Shim YM, Han J, Um SW. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. *Respirology*. 2010 Nov;15(8):1179-84.
  6. Gupta R, Park HY, Kim H, Um SW. Endobronchial inflammatory polyp as a rare complication of endobronchial ultrasound-transbronchial needle aspiration. *Interact Cardiovasc Thorac Surg*. 2010 Sep;11(3):340-1.
  7. Lee JH, Jung EJ, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Shim YM, Kim J, Han J, Um SW. Treatment outcomes of patients with adenoid cystic carcinoma of the airway. *Lung Cancer* 2011 May;72(2):244-9.
  8. Jung EJ, Lee JH, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Shim YM, Um SW. Treatment Outcomes for Patients with Synchronous Multiple Primary Non-small Cell Lung Cancer. *Lung Cancer* 2011 Aug;73(2):237-242. *Lung Cancer*.
  9. Jhun BW, Park HY, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Han J, Um SW. Nodal stations and diagnostic performances of EBUS-TBNA in patients with non-small cell lung cancer. *J Korean Med Sci*. 2012 Jan;27(1):46-51
  10. Park HY, Hahm CR, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Um SW. Serum VEGF and angiopoietin-2 are associated with the severity of systemic inflammation rather than the presence of hemoptysis in patients with inflammatory lung disease. *Yonsei Med J*. 2012 Mar 1;53(2):369-76.
  11. Verma A, Kang YR, Kim H, Um SW. Ultrasound guided fine needle aspiration of lung mass via trans-esophageal approach using endobronchial ultrasound bronchoscope. *Thoracic Cancer*. 2012 Aug;3:280-283.
  12. Jeon EJ, Park HK, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OS, Ki CS, Kim JW, Shim YM, Um SW. The role of pleural fluid MAGE RT-nested PCR in the diagnosis of malignant pleural effusion. *Thoracic Cancer*. 2012 Nov; 3:320-325.
  13. Chang B, Hwang JH, Choi YH, Chung MP, Kim H, Kwon OJ, Lee HY, Lee KS, Shim YM, Han J, Um SW. Natural History of Pure Ground-Glass Opacity Lung Nodules Detected by Low-Dose Computed Tomography. *Chest* 2013 Jan; 143(1): 172-178.
-

14. Kang YR, Kim SA, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Kang ES, Um SW. Toxocariasis as a cause of new pulmonary infiltrates. *Int J Tuberc Lung Dis*. 2013 Mar; 17(3): 412-417.
15. Lim SY, Lee KJ, Jeon K, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Um SW. Classification of Broncholiths and Clinical Outcomes. *Respirology*. 2013 May; 18(4): 637-42.
16. Jhun BW, Lee KJ, Jeon K, Suh GY, Chung MP, Kim H, Kwon OJ, Sun JM, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KS, Han J, Um SW. Clinical Applicability of Staging Small Cell Lung Cancer According to the Seventh Edition of the TNM Staging System. *Lung Cancer*. 2013 Jul;81(1):65-70. 2013 Mar 21.
17. Kang YR, Park HY, Jeon K, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YL, Han J, Um SW. EGFR and KRAS mutation analyses from specimens obtained by bronchoscopy and EBUS-TBNA. *Throacic Cancer*. 2013 Aug; 4 (3): 264-272.
18. Han SG, Yoo H, Jhun BW, Park HY, Suh GY, Chung MP, Kim H, Kwon OJ, Han J, Um SW. The Role of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Recurrent Non-small Cell Lung Cancer after Surgery. *Intern Med*. 2013 Sep;52(17):1875-81.
19. Maeng CH, Lee HY, Kim YW, Choi MK, Hong JY, Jung HA, Lee KS, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Um SW, Ahn MJ. High-Throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients. *Anticancer Res* 2013 Nov;33(11):5127-33.
20. Lee KJ, Suh GY, Chung MP, Kim H, Kwon OJ, Han J, Um SW. Combined Endobronchial and Transesophageal Approach of an Ultrasound Bronchoscope for Mediastinal Staging of Lung Cancer. *PLoS ONE*. 2014 Mar; 9(3): e91893
21. Um SW, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H. Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2015 Feb;10(2):331-7.
22. Jhun BW, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Lee KS, Han J, Kim J. Preoperative flexible bronchoscopy in patients with persistent ground-glass nodule. *PLOS ONE* 2015 Mar 24;10(3):e0121250.
23. Um SW, Joung JG, Lee H, Kim H, Kim KT, Park J, Hayes DN, Park WY. Molecular Evolution Patterns in Metastatic Lymph Nodes Reflect the Differential Treatment Response of Advanced Primary Lung Cancer. *Cancer Res*. 2016 Nov 15;76(22):6568-6576.
24. Um SW, et al. Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer. *Clin Epigenetics*. 2017 Dec 20;9:131.
25. Lee H, Joung JG, Shin HT, Kim DW, Kim Y, Kwon OJ, Shim YM, Lee HY, Lee KS, Choi YL, Park WY, Hayes DN, Um SW. Genomic alterations of ground-glass nodular lung adenocarcinoma. *Sci Rep*. 2018; 8:7691
26. Lee H, Joung JG, Shin HT, Kim DW, Kim Y, Kwon OJ, Shim YM, Lee HY, Lee KS, Choi YL, Park WY, Hayes DN, Um SW. Genomic alterations of ground-glass nodular lung adenocarcinoma. *Sci Rep*. 2018; 8:7691
27. Shin SH, Jeong BH, Jhun BW, Yoo H, Lee K, Kim H, Kwon OJ, Han J, Kim J, Lee KS, Um SW. The Utility of Endosonography for Mediastinal Staging of Non-Small Cell Lung Cancer in Patients with Radiological N0 Disease. *Lung Cancer*. 2020 Jan;139:151-156.

28. Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW. Prognostic value of SUVmax on <sup>18</sup>F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. *PLoS One*. 2020;15(2):e0229299.
29. Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, Bae JS, Lee S, Lee HS, Choi MY, Jeon BH, Jeong BH, Lee K, Kim HK, Kim J, Um SW. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. *Anticancer Res*. 2020;40(6):3435-3444.
30. Jeong BH, Um SW. First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. *Ann Transl Med* 2018;6(3):62-64.
31. Jeong BH, Um SW. Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer. *J Thorac Dis*. 2019 Jan;11(1):39-41.
32. Gil HI, Um SW. The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer. *J Thorac Dis*. 2020;12(3):153-155.
33. Shin SH, Jeong BH, Jhun BW, Yoo H, Lee K, Kim H, Kwon OJ, Han J, Kim J, Lee KS, Um SW. The Utility of Endosonography for Mediastinal Staging of Non-Small Cell Lung Cancer in Patients with Radiological N0 Disease. *Lung Cancer*. 2020 Jan;139:151-156.
34. Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW. Prognostic value of SUVmax on <sup>18</sup>F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. *PLoS One*. 2020;15(2):e0229299.
35. Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, Bae JS, Lee S, Lee HS, Choi MY, Jeon BH, Jeong BH, Lee K, Kim HK, Kim J, Um SW. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. *Anticancer Res*. 2020;40(6):3435-3444.
36. Choi Y, Kim KH, Jeong BH, Lee KJ, Kim H, Kwon OJ, Kim J, Choi YL, Lee HY, Um SW. Clinicoradiopathological Features and Prognosis According to Genomic Alterations in Patients With Resected Lung Adenocarcinoma. *J Thorac Dis*. 2020 Oct;12(10):5357-5368.
37. Clinical T category for lung cancer staging: A pragmatic approach for real-world practice. Choi Y, Kim SH, Kim KH, Choi Y, Park SG, Sohn I, Kim HS, Um SW, Lee HY. *Thorac Cancer*. 2020 Dec;11(12):3555-3565.
38. Im Y, Lee H, Lee HY, Baek SY, Jeong BH, Lee K, Kim H, Kwon OJ, Han J, Lee KS, Ahn MJ, Kim J, Um SW. Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer. *Transl Lung Cancer Res* 2021 Nov;10(11):4130-4140. doi: 10.21037/tlcr-21-677
39. Kim BK, Jang JH, Kim JW, Shin SH, Jeong BH, Lee K, Kim H, Kwon OJ, Ahn MJ, Um SW. Clinical utility of plasma cell-free DNA EGFR mutation analysis in treatment-naïve stage IV non-small cell lung cancer patients. *J Clin Med*. 2022 Feb 21;11(4):1144.
40. Kang N, Kim KH, Jeong BH, Lee K, Kim H, Kwon OJ, Ahn MJ, Cho J, Lee HY, Um SW. The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. *Cancer Res Treat*. 2022;54(3):817-826.
41. Kim BG, Um SW. A narrative review of the clinical approach to subsolid pulmonary nodules. *Ann Transl Med*. 2023 Mar 15;11(5):217. doi: 10.21037/atm-22-5246.
42. Choi H, Im Y, Jeong BH, Lee K, Kim H, Um SW. Clinical characteristics of miliary pulmonary metastases in non-small cell lung cancer. *Thoracic Cancer*. 2023 Aug;14(22):2168-2176. doi: 10.1111/1759-7714.15003.